IBAB:EBR
Ion Beam Applications SA
16,38 €
arrow_upward
+1,11%(+0,18) 1 d
16 okt., 17:35:27 GMT+2 · EUR
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för IBAB …
Öppen
16,20 €
Högt
16,56 €
Lågt
16,12 €
Börsvärde
489,36 mn
Genomsn. vol.
14,82 tn
Volym
17,31 tn
Utdelning
1,07 %
Kvartalsvis utdelning
0,04 €
Ex-utdelningsdatum
15 juni 2026
P/E-tal
20,58
52v högst
17,76 €
52v lägst
9,90 €
EPS
0,80 €
Utestående aktier
30,28 mn
Antal anställda
2 tn
Öppen
16,20 €
Högt
16,56 €
Lågt
16,12 €
Börsvärde
489,36 mn
Genomsn. vol.
14,82 tn
Volym
17,31 tn
Utdelning
1,07 %
Kvartalsvis utdelning
0,04 €
Ex-utdelningsdatum
15 juni 2026
P/E-tal
20,58
52v högst
17,76 €
52v lägst
9,90 €
EPS
0,80 €
Utestående aktier
30,28 mn
Antal anställda
2 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
Yahoo Finance
·
för 23 timmar sedan
IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
TipRanks
·
för 1 dag sedan
IBA wins major U.S. contract to build national PET radiopharmaceutical network
Profil
IBA is a medical technology company based in Louvain-la-Neuve. The company was founded in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain and became a university spin-off. It employs about 1500 people in 40 locations. The company developed cyclotrons and integrated proton therapy centers is active in the field of proton therapy, dosimetry, radiopharmacy solutions and industrial sterilisation.
IBA installed its first proton therapy equipment for Boston's Massachusetts General Hospital in 2001, and for University of Pennsylvania's Proton Center in 2009.
It supplied equipment and services to Proton Partners International which was developing three proton beam therapy centers in the United Kingdom.
In 2017, IBA invested €16 million in the construction of a new logistics and production center in Louvain-la-Neuve. Wikipedia
Om Ion Beam Applications SA